Communication lors des congrès

 

 

ANRS IPERGAY    

Beatrice Bercot, Aymeric Braille, Diane Carrette, Isabelle Charreau, Nathalie Schnepf, Constance Delaugerre, Laurent Cotte, Cécile Bébéar, Pialoux Gilles, Catherine Capitant, Francois Raffi, Jean-Michel Molina. Clonality and molecular resistance to tetracyclines of Neisseria gonorrhoeae among men who have sex with men using post-exposure prophylaxis with doxycycline. 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, 18-21 April 2020.

Marine Pillet, Eric Cua, Catherine Capitant, François Raffi, Christian Chidiac, Julie Chas, Cécile Tremblay, Armelle Pasquet, Brigitte Guillon, Bruno Spire, Constance Delaugerre, Laurence Meyer, Guillemette Antoni, Jean-Michel Molina. Risk Factors for HIV Infection among MSM in the ANRS IPERGAY PrEP Trial.Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, USA 2019, Abstract Poster.

Geoffroy Liegeon, Guillemette Antoni, Gilles Pialoux, Laurent Cotte, Cécile L. Tremblay, Catherine Capitant, Eric Cua, François Raffi, Eric Senneville, Pierre Charbonneau, Soizic Le Mestre, Veronique Dore, Laurence Meyer, Jean-Michel Molina. Changes in kidney function among MSM initiating on-demand TDF/FTC for HIV PrEP. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, USA 2019, Abstract Poster discussion.

Beatrice Bercot, Isabelle Charreau, Clotilde Rousseau, Constance Delaugerre, Christian Chidiac, Gilles Pialoux, Catherine Capitant, Nadege Bourgeois-Nicolaos, François Raffi, Sabine Pereyre, Eric Senneville, Laurence Meyer, Cecile Bebear, Jean-Michel Molina. High Prevalence And Antibiotic Resistance of M Genitalium Infections in MSM on PrEP. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, USA 2019, Abstract Poster.

Laurent Cotte, David Veyer, Isabelle Charreau, Jean Francois Fléjou, Hélène Péré, Eric Cua, Julie Chas, Isabelle Heard, Constance Delaugerre, Catherine Capitant, Jean-Michel Molina and ANRS IPERGAY Study group. Anal, oral and genital distribution of HPV in PrEP-users MSM: results at baseline of the ANRS IPERGAY HPV sub-study. 22nd International AIDS conference, Amsterdam, the Netherlands 2018, Abstract TUPEB056. Poster.

Thuy Nguyen, Constance Delaugerre, Marc-Antoine Valantin, Emmanuelle Netzer,  Pierre-Marie Girard, Nesrine Day, Georges Kreplak, Gilles Pialoux, Jean Michel Molina, Vincent Calvez, Anne-Geneviève Marcelin, Eve Todesco. Shared HCV transmission networks among HIV-1 positive and HIV-1 negative men having sex with men in Paris. 22nd International AIDS conference, Amsterdam, the Netherlands 2018, Abstract THAB0203. Oral presentation.

Antoni G, Pintado C, Delaugerre C, Meyer L, Molina JM. Is Prevalence of Early HIV-Infection at Baseline Correlated with HIV Incidence: An analysis of 10 PrEP trials. 22nd International AIDS conference, Amsterdam, the Netherlands 2018, Abstract WEPEC 318. Poster.

Chas J, Peytavin G, Carette D, Fabresse N, Charreau I, Capitant C, Roux P, Cua E, Cotte L, Pasquet A, Raffi F, Meyer L, Pialoux G, Molina JM, Alvarez JC. Chemsex drugs use by hair analysis among MSM in the ANRS IPERGAY trial. Conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA 2018, Abstract 2397.

Bauer R, Netzer E, Pintado C, Capitant C, Cua E, Etien N, Pialoux G, Chidiac C, Etienne C, Raffi F, Pasquet A, Dore V, Meyer L, Molina JM and the ANRS Ipergay Study Group. Coverage of Sex Events With On Demand PrEP - A MEMS sub-study of the IPERGAY trial. Conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA 2018, Abstract 1610.

Chaix ML, Charreau I, Delaugerre C, Mahjoub N, Siguier M, Capitant C, Tremblay C, Raffi F, Cua E, Pialoux G, Cotte L, Pasquet A, Meyer L, Molina JM and the ANRS IPERGAY study group. Effect of On Demand Oral PrEP with TDF/FTC on HSV-1/2 Incidence among MSM. Conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA 2018, Abstract 1029

Gras J, Mahjoub N, Charreau I, Cotte L, Tremblay C, Chas J, Raffi F, Cua E, Guillon B, Guigue N, Chaix Baudier ML, Meyer L, Molina JM, Delaugerre C. HCV RNA and Antigen Detection for Diagnosis of Acute Hepatitis C Among MSM On PrEP. Conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA 2018, Abstract 1573.

Di Ciaccio M, Sagaon-Teyssier L, Suzan-Monti M, Mmadi-mrenda B, Cua E, Pialoux G, Leturque N, Foubert V, Préau M, Molina JM, Spire B. Impact of risk perception trajectory on PrEP and condom use among Men who have Sex with Men during the Open-Label-Extension of the ANRS-IPERGAY trial. Poster. IAS 2017

Di Ciaccio M, Suzan-Monti M, Chidiac C, Bernaud C, Cheret A, Pialoux G, Cua E, Saouzanet M, Netzer E, Spire B, Molina JM, Préau M. Attitudes about PrEP among physicians who participated in the Open-Label Extension of the ANRS-IPERGAY trial: a qualitative study. Poster. IAS 2017

Antoni G, Tremblay C, Charreau I, Cua E, Rojas-Castro D, Hall N, Chas J, Huleux T, Spire B, Capitant C, Cotte L, Meyer L, Molina JM, and the ANRS Ipergay Study Group. On-Demand PrEP with TDF/FTC remains highly effective among MSM with infrequent sexual intercourse: A sub-study of the ANRS IPERGAY trial. Présentation orale. IAS 2017

Roux P, Fressard L, Suzan-Monti M, Chas J, Capitant C, Meyer L, Molina JM, Pialoux G, Spire B. Is on-demand HIV pre-exposure prophylaxis (PrEP) a suitable tool for men who have sex with men (MSM) who participate in chemsex? Results from a sub-study of the ANRS-IPERGAY trial. Présentation orale. IAS 2017

Suzan-Monti M, Cotte L, Fressard L, Cua E, Capitant C, Meyer L, Molina JMM , Spire B. Partner notification of sexually transmitted infections among MSM on PrEP: a sub-study of the ANRS-IPERGAY open label extension. Poster discussion session. IAS 2017

Chaillon A, Delaugerre C, Mahjoub N, Brenner B, Capitant C, Carette D, Nere ML, Pialoux G, Cua E, Cotte L, Tremblay C, Spire B, Wainberg M, Smith DM, Goujard C, Meyer L, Molina JM, and Chaix ML. In Depth Sampling of High Risk Populations to Characterize HIV Transmission Epidemics among Young MSM using PrEP in France and Quebec. Poster. IAS 2017

Molina Sagaon-Teyssier L, Suzan-Monti M, Rojas Castro D,  Hall N,  Capitant C, Chidiac C, Tremblay C, Spire B, Molina JM, for the ANRS IPERGAY Study Group. PrEP and Condom Use in High Risk MSM in the ANRS IPERGAY Trial. Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, USA, 2016. Abstract #887. Poster,

Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas-Castro D, Cua E, Pasquet A, Bernaud C, Rozenbaum W, Delaugerre C, Doré V, Le Mestre S, Simon M.-C, Delfraissy J.-F, Meyer L, ANRS IPERGAY Study Group. Efficacy of On Demand PrEP with TDF-FTC in the ANRS IPERGAY Open-Label Extension Study. 21th International AIDS Conference (AIDS 2016), Durban, 18-22 July 2016. Abstract WEAC0102. Oral presentation.

Durand-Zaleski I, Mutuon P, Charreau I, Tremblay C, Rojas D, Chas J, Chidiac C, Capitant C, Spire B, Meyer L, and Molina JM for the ANRS IPERGAY study group. Cost Effectiveness of On Demand PrEP in Men who have Sex with Men (MSM) in the ANRS IPERGAY Study. 21th International AIDS Conference (AIDS 2016), Durban, 18-22 July 2016. Abstract THAE0304. Oral presentation. 

Sagaon-Teyssier L, Monti MS, Rojas-Castro D, Hall N, Capitant C, Chidiac C, Tremblay C, Spire B, Molina JM, et le groupe ANRS IPERGAY. Utilisation de la PrEP et du préservatif parmi les HSH dans l' essai ANRS IPERGAY. 8ème conférence internationale francophone VIH/Hépatites AFRAVIH, Bruxelles, avril 20-23, 2016. Poster PV225 

Molina JM, Charreau I, Spire B, Cotte L, Pialoux G, Capitant C, Tremblay C, Rojas-Castro D, Meyer L, et le groupe ANRS IPERGAY. La PrEP  (TDF/FTC) à la demande dans la phase en ouvert de l'essai ANRS IPERGAY. 8ème conférence internationale francophone VIH/Hépatites AFRAVIH, Bruxelles, avril 20-23, 2016. Présentation orale

Delaugerre C, Charreau I, Mahjoub N, Cua E, Pasquet A, Hall N, Chaix ML, Antoni G, Schneider V, Pialoux G, Molina JM pour le groupe ANRS IPERGAY. Evaluation des tests rapides pour le diagnostic du VIH-1 dans l'essai ANRS IPERGAY. 8ème conférence internationale francophone VIH/Hépatites AFRAVIH, Bruxelles, avril 20-23, 2016. Présentation orale

Molina JM, Charreau I, Spire B , Cotte L, Pialoux G, Capitant C, Tremblay C , Rojas Castro D, Meyer L and the ANRS IPERGAY Study Group.  On Demand PrEP with Oral TDF-FTC in the Open-Label Phase of the ANRS IPERGAY Trial. Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, USA, 2016. Abstract #886. 

Sagaon-Teyssier L, Suzan-Monti M, Rojas Castro D,  Hall N,  Capitant C, Chidiac C, Tremblay C, Spire B, Molina JM, for the ANRS IPERGAY Study Group. PrEP and Condom Use in High Risk MSM in the ANRS IPERGAY Trial. Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, USA, 2016. Abstract #887.

Delaugerre C, Charreau I, Mahjoub N, Cua E, Pasquet A, Hall N, Chaix ML, Antoni G, Molina JM and the ANRS IPERGAY Study Group.
Usefulness of Rapid Tests for HIV Diagnosis in the ANRS IPERGAY Trial.Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, USA, 2016. Abstract #522.

J. Lambec, M-A. Danet1, A. Djessima Taba,  K. Moudachirou, X. Teruin, S. Rouby, N. Dumon, V. Pechenot, S. Bagge, B. Dos Santos, L. Babonnaud, V. Coquelin , A. McKenzie, M. Blanchette, L. Cotte, C. Chidiac, C. Etienne, A. Pasquet, F. Raffi, C. Bernaud, C. Tremblay, G. Pialoux, J-M. Molina, C. Capitant, B. Spire1, M. Suzan-Monti, M. Préau, S. Benayoun, D. Rojas Castro.L’accompagnement communautaire : une collaboration novatrice dans un essai médical. 2ème Journée Scientifique Sidaction, 12 février 2016. Présentation orale.

Molina JM, Capitant C, Spire B, Pialoux G, Chidiac C, Charreau I, Tremblay C, Meyer L, Delfraissy JF and the ANRS Ipergay Study Group. On Demand PrEP With Oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle 2015. Abstract 23LB.

Fonsart J, Capitant C, Spire B, Cotte L, Pialoux G, Lorente N, Peytavin G, Charreau I, Aboulker JP, Molina JM and the ANRS Ipergay study group. High Adherence Rate to Intermittent Oral PrEP with TDF/FTC among High Risk MSM (ANRS Ipergay). 20th International AIDS Conference, Melbourne, Australia, July20-25, 2014 (oral presentation).

Stéphane Morel, Patrick Brunet, Marc-Antoine Danet, Xavier Teruin, Sylvie Rouby, Thomas Cepitelli, Nicolas Dumon, Khafil Moudachirou, Jimmy Lambec, Vincent Péchenot, Romain Porion, Vincent Coquelin. Le rôle des accompagnateurs dans l’essai ANRS Ipergay. (France) 7ème conférence internationale francophone VIH/Hépatites AFRAVIH, Montpellier, avril 27-30, 2014, Poster L1.9.

Xavier Mabire, Gabriel Girard, Marion Mora, Marie SuzanMonti, JeanMarie LeGall, Nicolas Lorente, Catherine Capitant, JeanMichel Molina, Bruno Spire, Marie Préau. Motivation et adhérence des participants d'un essai de prophylaxie pré‐exposition au VIH (ANRS-Ipergay). 7ème conférence internationale francophone VIH/Hépatites AFRAVIH, Montpellier, avril 27-30, 2014, Poster L1.3

Molina JM, pour le consortium IPERGAY. Traitement antirétroviral « à la demande » en prophylaxie pré-exposition de l’infection par la VIH chez des hommes ayant des rapports sexuels avec des hommes : Présentation de l’essai ANRS IPERGAY. 6ème Conférence Francophone VIH/SIDA (AFRAVIH), Genève, mars 25-28, 2012, Poster # 655

ANRS EP46 NOVAA

Durier C, Mercier-Delarue S ,Colin De Verdiere N, Meiffrédy V, Matheron S, Samri A, Resch M, Marchand L, Autran B, Launay O, Simon F. Long term immune response to yellow fever vaccination in HIV-infected and non-infected adults: ANRS EP46 study. 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, 18-21 April 2020.

Samri A,  Durier C,  Colin de Verdiere N, Meiffredy V, Launay O,  Matheron S,  Mercier-Delarue S, Aude Boulay, Aboulker JP, Molina JM, Simon F, and Autran B. Low T cell Immunogenicity of the Yellow Fever Vaccine in HIV-Infected Patients. Poster IAS 2017

ANRS 147 OPTIPRIM

Chéret A, Heitzmann J, Mélard A, Durier C, David L, Muller-Trutwin M, Chennebault J-M, Lécuroux C, Rouzioux C, Meyer L for the ANRS 147 OPTIPRIM Team. Impact of cART & Systemic inflammation on Semen HIV-1 Reservoir in Primary Infection. Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, USA, 2016. Abstract #351.

ANRS HC30 QUADRIH

Lionel Piroth, Hubert Paniez, Corine Vincent, Karine Lacombe, David Rey, Didier Neau, Jacques Izopet, Alpha Diallo, Laurence Meyer, Jean-Michel Molina, on behalf of the ANRS HC30 Quadrih study group. High efficacy of daclatasvir/asunaprevir/PR in HIV/HCV1-4 Null Responders (ANRS HC30). Conference on Retroviruses and Opportunistic Infections (CROI), Seattle 2015. Abstract 146.

ANRS HC26 TELAPREVIH    

Laurent Cotte, Aurélie Barrail-Tran, Corine Vincent, Marc-Antoine Valantin, Isabelle Fournier, Karine Lacombe, Stéphane Chevaliez, Jean-Pierre Aboulker, Anne-MarieTaburet, Jean-Michel Molina -  ANRS HC26 study group. Telaprevir Increases Ribavirin Toxicity Through eGFR Decrease in HIV-HCV Coinfected Patients. 21th Conference on Retroviruses and Opportunistic Infections, Boston, 2014, Poster #664LB

Laurent Cotte, Corine Vincent, Philippe Sogni, Isabelle Fournier, Hugues Aumaitre, Pierre De Truchis, Isabelle Rosa, Stéphane Chevaliez, Jean-Pierre Aboulker, Jean-Michel Molina -  ANRS HC26 study group.Telaprevir in Treatment-Experienced HIV-HCV G1 Coinfected Patients (ANRS HC26 TelapreVIH). 21th Conference on Retroviruses and Opportunistic Infections, Boston, 2014, Poster #668 and themed discussion

Laurent Cotte. Retraitement avec Telaprevir ou Boceprevir chez les patients coinfectés VIH-VHC génotype 1 Essais ANRS HC26 TelapreVIH et HC27BocepreVIH. Journée annuelle du TRT-5, Paris, octobre 2013, Présentation.

Laurent Cotte, Joséphine Braun, Philippe Sogni, Corine Vincent, Marc-Antoine Valantin, Daniel Vittecoq, Christian Michelet, Dominique Batisse, PhilippeMorlat, Anne Gervais, Jean-Michel Pawlotsky, Jean-Pierre Aboulker, Jean-Michel Molina, ANRS HC26 study group.High End-Of-Treatment (EOT) Response Rate with Telaprevir-PegIFN-RBV in Treatment-Experienced HIV Coinfected Patients with HCV genotype 1: ANRS HC26 TelapreVIH Study. 64th American Association for the Study of Liver Diseases (AASLD), Washington, 2013, Poster   

Cotte L, Braun J, Lascoux-Combe C, Vincent C, Pol S, Valantin MA, Lacombe K, Neau D, Aboulker JP, Molina JM on behalf of the ANRS HC26 study group. High Early Virological Response with Telaprevir-PegIFN-RBV in treatment-experienced, HCV genotype 1, HIV coinfected patients: ANRS HC26 TelapreVIH Study. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, 2013, Oral abstract #36

NEOMERO STUDIES

Xueyi Zhang, Timothy Ciesielski, Jaquelaine Bartlett, Giorgio Sirugo, Scott M. Williams for the NeoMero Consortium. A GWAS of Neonatal Sepsis shows significant genetic differences between males and females. abstract for the American Society of Human Genetics 2019 meeting, October 15-19 Houston.

Lutsar I, Chazallon C, Trafojer U, Abdelkader B, Aboulker JP, Meiffrédy V, Esposito S, Fournier I, Heath PT, Ilmoja ML, Katragkou A, Mitsiakos G, Netzer E, Picault L, Pugni L,  Roilides E, Saidi Y,  Sarafidis K,  Usonis V and  Metsvaht T.  European multicenter network to evaluate pharmacokinetics, safety and efficacy of meropenem in neonatal late-onset sepsis and meningitis. 31st ESPID Milan, Italy, May 28 - June 1, 2013, Poster.

ANRS HB02 VAC-ADN   

Fontaine H, Chazallon C, Mancini-Bourgine M, Lebray P, Buffet C, Kahi S, Godon O, Meritet JF, Saïdi Y, Michel ML, Scott-Algara D, Aboulker JP, Pol S and the ANRS HB 02 VAC-ADN study group. Relapse after analogues treatment discontinuation is not prevented by DNA vaccination in chronic hepatitis B (ANRS HB 02 VAC-ADN). The 46th EASL, Berlin, 2011, Late-breakers, abstract 12.

ANRS COV1 - COHVAC    

Christine Durier, Corinne Desaint, Jean-Daniel Lelièvre, Benjamin Silbermann , Gilles Pialoux, Lise Cuzin, Bénédicte Bonnet, Olivia Zaegel-Faucher, Ben Abdelkader, Carine Lascoux, Zeynep Yalcin-Sumer, Amel Bouakane, Alpha Diallo, Christelle Paul, Jean-Pierre Aboulker, Bruno Spire, Laurence Meyer, Odile Launay, ANRS COHVAC Study Group, Paris and Vaccine Research Institute (VRI), Créteil, France. Final Report of ANRS COV1-COHVAC Cohort of Healthy Volunteers From Preventive HIV-1 Vaccine Trials Poster P05.05

Desaint C,  Durier C, Lelièvre JD,  Silbermann B,  Pialoux G,  Cuzin L, Poizot-Martin I, Morineau P,  Yalcin Sumer Z, Lascoux C, Bouakane A, Diallo A, Aboulker PJ, Spire B, Meyer L,  Launay O, ANRS COHVAC Study Group, Paris, France and Vaccine Research Institute (VRI), Créteil, France. First report after early termination of ANRS COV1-COHVAC cohort of healthy volunteers from preventive HIV-1 vaccine trials. Poster, IAS 2017 

C. Desaint, C. Durier, J-D. Lelièvre, B. Silbermann, G. Pialoux, L. Cuzin, I. Poizot-Martin, P. Morineau, A. Bouakane, B. Spire, Y. Lévy, J-P. Aboulker, O. Launay. A Update of the Long-term Follow-up of Healthy Volunteers from Preventive HIV-1 Vaccine trials: ANRS COV-1-COHVAC Cohort. HIV R4P, Cap Town,  2014

O. Launay, C. Durier, C. Desaint, B. Silbermann, J. Lelièvre, L. Slama, I. Poizot-Martin, L. Cuzin, P. Morineau Le Houssine, V. Doré, B. Spire, F. Linard, V. Rieux, A. de Saunière, J. Guillet, Y. Lévy, J.P. Aboulker for the ANRS COHVAC Study Group . A prospective study for evaluating long term safety of preventive HIV-1 vaccine candidates: the ANRS COHVAC Cohort. AIDS Vaccine, Seattle 2007, poster P06-28.

 C. Durier, C. Desaint, O. Launay, B. Silbermann, J. Lelièvre, B. Phung, L. Slama, B. Bonnet, L. Cuzin, I. Poizot-Martin, P. Duchet-Niedziolka, V. Rieux, V. Doré, Y. Lévy, J. Aboulker, B. Spire for the ANRS HIV Vaccine Network and the ANRS COHVAc Study Group. Psychosocial consequences of participation in HIV preventive vaccine trials: a cross-sectional study in ANRS COV1-COHVAC cohort. AIDS Vaccine, Atlanta 2010, présentation orale OA03.01.

Durier C, Desaint C, Silbermann B, Lelièvre J-D, Slama L, Morineau-Le Houssine P, Cuzin L, Poizot-Martin I, Aboulker J-P, Launay O, and ANRS COV1-COHVAC Study Group. Long-term Vaccine-induced HIV Seropositivity among HIV-uninfected Healthy Volunteers in ANRS COV1-COHVAC Cohort. 18th CROI 2011, Feb27-Mar2, 2011, Boston, USA, Abstract #372.

Durier C, Desaint C, Silbermann B, Lelièvre JD, Phung B, Slama L, Morineau-Le Houssine P, Cuzin L, Poizot-Martin I, Duchet- Niedziolka P, Dore V, Rieux V, Ross AL, Lévy Y, Pialoux G, Aboulker JP, Spire B, Launay O and the ANRS HIV Vaccine Network/VRI. Long-Term Consequences of Participation in HIV Preventive Vaccine Trials Among Healthy Uninfected Subjects: The ANRS COHVAC Cohort. AIDS RESEARCH AND HUMAN RETROVIRUSES, 27(10), A73-A73. AIDS Vaccine 2011, Sep12-Sep15, 2011, Bangkok,Thailand. 

ANRS 151 - HIFLUVAC 

O. Launay, C. Desaint, C. Durier, P. Loulergue, X. Duval, G. Pialoux, J. Ghosn, F. Raffi, J. Reynes, J.P. Aboulker, and Natl Network of Clin Investigation in Vaccinology and ANRS. Immunogenicity of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant in HIV+ adults: preliminary report of the ANRS 151 randomized HIFLUVAC trial.17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, February 16-19, 2010, abstract 804LB.

Durier C, Desaint C, Colin de Verdière N, Girard P-M, Lévy Y, Rey D, Jacomet C, Lucht F, Aboulker J-P, Launay O, and ANRS 151 Study Group and REIVAC Network. Durability of the Immune Response after Vaccination with 2 Doses of Influenza A H1N1v 2009 Vaccine Formulated with and without AS03A-adjuvant in HIV+ Adults: ANRS 151 Randomized HIFLUVAC Trial. 18th CROI 2011, Feb27-Mar2, 2011, Boston, USA, Abstract #909

ANRS 150-PENTA 18-KONCERT 

D Bastiaans, S Forcat, H Lyall, T Cressey, S Chalermpantmetagul, Y Saïdi, C Koenigs, D Nayagam, A Compagnucci, S Montero, L Harper, C Giaquinto, E Colbers, D Burger. Pharmacokinetics of paediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands. 31st Annual Meeting of the ESPID- May 28 – June 1, 2013, Milan: Poster discussion Abstract A-534-0018-00429.  

D Bastiaans, S. Forcat, H.E.G. Lyall, T.R. Cressey, S. Chalermpantmetagul, Y. Saïdi, H.J. Scherpbier, A. Warris, A. Compagnucci, C. Giaquinto, E.P. Colbers, D.M. Burger on behalf of PENTA KONCERT Study Group.6th Netherlands Conference on HIV Pathogenesis, Prevention and Treatment. November 27, 2012. Pharmacokinetics of 100/25 mg lopinavir/ritonavir tablets in children when dosed twice daily according to FDA weightbands. The Royal Tropical Institute (KIT), Amsterdam: Poster Abstract 29.

Bastiaans DET, Forcat S, Lyall HEG, Cressey TR, Chalermpantmetagul S, Saïdi Y, Noguera T, Fortuny C, Compagnucci A, Bleier J, Giaquinto C, Colbers EP, Burger DM. Pharmacokinetics of 100/25 mg lopinavir/ritonavir tablets in children when dosed twice daily according to FDA weight bands. 4th International Workshop on HIV pediatrics 2012. July 20-21, 2012. L'Enfant Plaza Hotel, Washington DC, USA. Poster 41

PENTA 16-BREATHER

Karina M. Butler On behalf of the BREATHER Trial Team.ART With Weekends Off Is Noninferior to Continuous ART in Young People on EFV+2NRTI. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle 2015. Abstract 38LB.

INSERM C09-33 - PREFLUVAC 
Launay O, Capitant C, Schmitz T, Chazallon C, Riethmuller D, Picone O, Poulain P, Lewin F, Jacqz-Aigrain E, Aboulker JP, Tsatsaris V, for theInserm PREFLUVAC Trial Group. Strong Immune Response to a Monovalent non-Adjuvanted 2009 Influenza A/H1N1v Vaccine in Pregnant Women. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, USA, September 12-15, 2010 Abstract G1-1338  

INSERM C09-32 - TRANSFLUVAC 
E. Morelon, C. Pouteil Noble, F. Thibault, S. Daoud, R. Cahen, C. Dollinger, N. Lecorre, I. Charreau, V. Meiffrédy, J-P. Aboulker, B. Autran, B. Barrou. Etude de Phase II évaluant l'immunogénicité et la tolérance d'un vaccin inactivé et sans adjuvant contre la grippe A (H1N1) après transplantation rénale (Etude Transfluvac INSERM C09-32). 12ème réunion commune Société de Néphrologie / Société Francophone de Dialyse, Bruxelles (Belgique), sept. 2010.

F. Thibault, C. Pouteil Noble, V. Meiffrédy, S. Daoud, R. Cahen, C. Dollinger, N. Lecorre, I. Charreau, J.P. Aboulker, B. Autran, B. Barrou, E. Morelon. Safety and Efficacy of an Inactivated, Unadjuvanted Vaccine Against the novel Influenza A Variant (H1N1v) in Renal Transplant Recipients (Transfluvac Study). Options for the Control of Influenza, Hong Kong, du 3 au 7 septembre 2010. 

Thibault F, Pouteil Noble C, Meiffrédy V V, Daoud S, Cahen R, Dollinger D, Lecorre N, Charreau I, Aboulker JP, Autran B, Morelon E, Barrou B. Safety and Efficacy of an Inactivated, Unadjuvanted Vaccine Against the Novel Influenza A Variant (H1N1v) in Renal Transplant Recipients (INSERM C09-32, Transfluvac Study). European Society for Organ Transplantation. September 2011, Glasgow, UK. Oral communication [Abstract 283]. 

Thibault F, Pouteil Noble C, Meiffrédy V V, Daoud S, Cahen R, Dollinger D, Lecorre N, Charreau I, Aboulker JP, Autran B, Morelon E, Barrou B. Safety and Efficacy of an Inactivated, Unadjuvanted Vaccine Against the Novel Influenza A Variant (H1N1v) in Renal Transplant Recipients (INSERM C09-32, Transfluvac Study). American Transplant Congress, Philadelphia Pennsylvania, USA, April 30-May 4, 2011. Oral communication [Abstract 540]. 

ANRS 148 - LIVERAL 

Caroline Barau, Joséphine Braun, Corine Vincent, Stéphanie Haïm-Boukobza, Jean-Michel Molina, Patrick Miailhes, Jean-Pierre Aboulker, Jean-Charles Duclos-Vallée, Anne-Marie Taburet, Elina Teicher and the ANRS 148 Study group. Pharmacokinetic study of raltegravir in HIV-infected patients with end stage liver disease : LIVERAL ANRS 148 study. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta , 2013, Abstract 528 Poster#J-115

Caroline Barau, Joséphine Braun, Corine Vincent, Stéphanie Haïm-Boukobza, Jean-Michel Molina, Patrick Miailhes, Jean-Pierre Aboulker, Jean-Charles Duclos-Vallée, Anne-Marie Taburet, Elina Teicher,and the ANRS 148 study group. Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease and further to liver transplantation: LIVERAL ANRS 148 study. VIII ème Congrès de Physiologie de Pharmacologie et de Thérapeutique. 22-24 Avril 2013- Angers-France, Poster

Elina Teicher, Joséphine Braun, Caroline Barau, Thomas Boulet, Véronique Eliette, Pascal Ralaimazava, Laurence Bonhomme, Chadi Abbara, Jean-Charles Duclos-Vallée, Anne-Marie Taburet. Raltegravir in HIV-Infected Liver Transplant Recipients. ANRS-148 LIVERAL. The 2011 Joint Congress of ILTS, ELITA, & LICAGE, Valencia, Spain June 22-25 (poster). 

ANRS 138 - EASIER 

Gallien S, Charreau I, S, Néré ML, Mahjoub, De castro, Aboulker JP, Molina JM, Delaugerre C. Rilpivirine-associated resistance in HIV-1 DNA in suppressed patients pretreated by NNRTIs. 21st Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, March 3-6, 2014.

N. De Castro, J. Braun, I. Charreau, G. Pialoux, L. Cotte, C. Katlama, F. Raffi, L. Weiss, P.M. Girard, Y. Yazdanpanah, C. Delaugerre, I. Madelaine-Chambrin, J.P. Aboulker and J.M. Molina . Switch from Enfuvirtide (ENF) to Raltegravir (RAL) in Highly Treatment-Experienced HIV-1 Infected Patients: A Randomized Open-Label Non-Inferiority Trial (Easier - ANRS 138). 48th ICAAC, Washington, USA, 25-28 oct. 2008. 

N. de Castro, J. Braun, I. Charreau, G. Pialoux, L. Cotte, C. Katlama, C. Delaugerre, I. Madelaine-Chambrin, J.P. Aboulker, J.M. Molina, and the ANRS 138 study group. Switch from enfuvirtide (E) to raltegravir (R) in highly treatment-experienced HIV-1 infected patients: A Randomized Open-Label Non-Inferiority Trial (Easier - ANRS 138)." 16th Conference on Retroviruses and Opportunistic Infections, Montreal, 2009, Abstract 572.

L. Goldwirt, J. Braun, N. de Castro, C. Allavena, C. Lascoux-Combe, B. Guillon, J.-L. Meynard, I. Charreau, A.-M. Taburet, J.-M. Molina, and the ANRS 138 study group. Tipranavir and Darunavir Pharmacokinetics in Patients Switching from Enfuvirtide to Raltegravir: a Sub-Study of the ANRS 138 EASIER Trial. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, 2009.

N. de Castro, J. Braun, I. Charreau, P. de Truchis, F. Jeanblanc, R. Verdon, L. Slama, J.L. Meynard, J.P. Aboulker, J.M. Molina and the ANRS 138 EASIER Study Group. Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug-Resistant HIV-1 Infected Patients: Final Results of the Randomized ANRS 138 Trial (EASIER). 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, 19-22 July 2009, Abstract 2058.

N. De Castro, J. Braun, I. Charreau, G. Pialoux, C. Katlama, C. Delaugerre, J.P. Aboulker, J.M. Molina, and the ANRS 138 study group . Switch de l’enfuvirtide pour le raltegravir chez des patients infectés par un VIH multi-résistant et bien contrôlés sous traitement : Résultats à S24 et S48 de l’essai Easier-ANRS 138. 8ème Séminaire de recherche clinique sur le VIH. CNIT. Paris La Défense, 4-5 Mai, 2009. 

N. De Castro, J. Braun, I. Charreau, G. Pialoux, C. Katlama, J.P. Aboulker, J.M. Molina, and the ANRS 138 study group. Switch de l’enfuvirtide pour le raltegravir chez des patients infectés par un VIH multi-résistant et bien contrôlés sous traitement : Résultats de l’essai Easier-ANRS 138. 10èmes Journées Nationales d’Infectiologie, Lyon, France, 10-12 Juin 2009.

C. Delaugerre, I. Charreau, J. Braun, M.L. Néré, N. De Castro, P. Yeni, J.M. Chennebault, A. Lafeuillade, J. Ghosn, F. Simon, J.P. Aboulker, J.M. Molina and the ANRS 138 study group. No evolution of HIV-1 total DNA and 2-LTR circles after 24 weeks of raltegravir-containing regimen: a sub-study of randomized EASIER-ANRS 138 trial. XVIII th International HIV Drug Resistance Workshop. Fort Myers, Florida, USA, June 9-13, 2009.

T. Boulet, N. De Castro, I. Charreau, F. Euphrasie, J. Reynes, P. Morlat, L. Piroth, B. Spire, J.M. Molina, J.P. Aboulker for the ANRS 138 - Easier study team. Impact on Health-Related Quality of Life of a Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug-Resistant HIV-1 Infected Patients. Results of the Easier ANRS 138 trial. 12th European AIDS Conference. Cologne, Germany, November 11-14, 2009.

C. Delaugerre, I. Charreau, J. Braun, M.L. Néré, N. De Castro, P. Yeni, J. Ghosn, F. Simon, J.P. Aboulker, J.M. Molina and the ANRS 138 study group. No Evolution of HIV-1 Total DNA and 2-LTR Circles after 48 Weeks of Raltegravir-Containing Therapy in Patients with Controlled Viremia: a Sub-Study of the Randomized EASIER-ANRS 138 Trial. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, February 16-19, 2010 #281. 

C. Delaugerre, I. Charreau, J. Braun, S. Delarue, M.L. Néré, N. De Castro, T. May, B. Marchou, J.M. Molina, J.P. Aboulker and the ANRS 138 study group. HIV-1 Genotypic Resistance Tests Performed in Cellular DNA are Less Informative than those Collected from Previous Plasma RNAs in Treatment Experienced Patients with Suppressed Viremia: a Sub-Study of EASIER-ANRS 138 Trial. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, February 16-19, 2010 #573. 

S. Rozlan, C. Codron, J. Dutrieux, S. Beq, I. Charreau, J. Braun, V. Eliette, B. Guillon, J.P. Aboulker, J.M. Molina, Y. Levy, C. Rabian and R. Cheynier. The impact of Raltegravir on TCR rearrangement processes may lead to reduced thymic output. A sub-study of the ANRS 138 Easier trial. 18th International AIDS Conference, Vienna (Austria), July 18-23, 2010.

Gallien S, Delaugerre C, Hu1 Z, Braun J, Charreau I, Euphrasie F, Aboulker JP, de Castro N, Molina JM, Kuritzkes D.R . Integrase Inhibitor Resistance Mutations in Treatment-Experienced HIV-1-Infected Patients with Low-Level Viremia receiving Raltegravir-Containing Antiretroviral Therapy: An ANRS 138-EASIER Trial Substudy. International HIV&Hepatitis Virus Drug Resistance Workshop and Curative Strategies, Dubrovnik (Croatia), June 8-12, 2010. Poster # 49. 

De Castro N., Braun J., Charreau I., Lafeuillade A., Viard JP, Allavena C., Aboulker JP and Molina JM and the ANRS 138 study group. Incidence and risk factors for liver enzymes elevations (LEE) in highly treatment-experienced patients switching from ENF (ENF) to RAL (RAL): Sub-study of the ANRS-138 Easier trial. 6th IAS Conference on HIV pathogenesis, treatment and prevention. 10-20 July 2011, ROME, ITALY International AIDS Society (poster). 

Silva Erika, Charreau Isabelle, Gourmel Bernard, Mourah Samia, Kalidi Issa, Guillon Brigitte, De Castro Nathalie , Aboulker Jean-Pierre , Braun Josephine, Molina Jean-Michel and the ANRS Easier study group . Decrease in Inflammatory and Coagulation Biomarkers in HIV-Infected Patients After Switching from Enfuvirtide (ENF) to Raltegravir (RAL) in the Randomized ANRS 138 EASIER Trial. 19th Conference on Retroviruses and Opportunistic Infections (CROI) 2012, March 5-8, Seattle, WA, US (poster). 

S Gallien, I Charreau, ML Néré, J Braun, N de Castro, P Yeni, J Ghosn, F Simon, JP Aboulker, JM Molina and C Delaugerre and the ANRS 138 study group. Integrated HIV-1 DNA Change after 48 Weeks of Raltegravir-Containing Therapy in Patients with Supressed Viremia: a Sub-Study of the EASIER-ANRS 138 Trial. Poster: The International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies, June 5-9 2012, Sitges, SPAIN. 

ANRS 133- PENTA 15

Jacqz-Aigrain, Farrelly L, Compagnucci A, Harrison L, Zhao W, Hamadache D, Welch S, Wintergerst U, Firtion G, Burger D. PENTA 15: plasma pharmacokinetic study of once versus twice daily abacavir and lamivudine as part of combination antiretroviral therapy in HIV-1 infected children aged 3 to 36 months. CROI 2009. Palais des congrès de Montréal, Canada, Poster S-154 

 Zhao W, Farrelly L, Compagnucci A, Harrison L, Jacqz-Aigrain E, Hamadache D, Welch S, Wintergerst U, Burger D on behalf of the PENTA Trial Steering Committee .PENTA 15: Once-daily abacavir and lamivudine as part of combination antiretroviral therapy to 48 weeks in HIV-1 infected children aged 3 to 36 months. 1st International Workshop on HIV Pediatrics, 17 – 18 July 2009, Cape Town, South Africa. Oral presentation

ANRS CO14 

E. Fontas, I. Kousignian, C. Pradier, C. Duvivier, I. Poizot-Martin, C. Durier, B. Jarousse, L. Weiss, Y. Lévy, D. Costagliola, and ANRS CO4 and CO14. Effect of Interleukin-2 therapy on lymphoma’s occurrence in HIV-infected patients. 13th Conference on Retroviruses and Opportunistic Infections, Denver, 2006, Abstract 824.

ANRS VAC16   

O. Launay, C. Durier, C. Desaint, B. Silbermann, A. Jackson, D. Salmon, G. Pialoux, B. Bonnet, I. Poizot-Martin, G. Gonzalez-Canali, L. Cuzin, M. Surenaud, C. Guérin, I. Bougault-Villada, J.G. Guillet (ANRS VAC16 trial) . Safety and immunogenicity of intradermal versus intramuscular administration of HIV lipopeptides in HIV uninfected adult volunteers. AIDS Vaccine, Montreal 2005, poster. 

C. Durier , O. Launay, C. Desaint , B. Silbermann, A. Jackson, G. Pialoux , B. Bonnet, I. Poizot-Martin , G. Gonzalez-Canali , L. Cuzin, D. Salmon, M. Surenaud , C. Guérin , I. Bourgault Villada, and J.G. Guillet  for the Agence Nationale de Recherche contre le SIDA (ANRS) VAC16 trial group . Dose sparing with intradermal injection of HIV lipopeptides in HIV uninfected adult volunteers: a randomized controlled study (ANRS VAC16 trial). AIDS Vaccine, Amsterdam 2006, Antiviral Therapy 2006; 11 (Suppl 2): P11-16. 

O. Launay, C. Desaint, B. Silbermann, A. Jackson, G. Pialoux, B. Bonnet, I. Poizot-Martin, L. Cuzin, S. Figueiredo, M. Surenaud, H. Gahery, J. Choppin, D. Salmon, C. Guérin, I. Bourgault-Villada, J. Guillet, C. Durier for the ANRS VAC16 Study Group . Long term immune responses induced by intradermal or intramuscular injection of HIV lipopeptides in HIV uninfected volunteers (ANRS VAC 16 trial). AIDS Vaccine, Seattle 2007, poster P06-05 

ANRS VAC18   

D. Salmon-Céron, C. Durier, C. Desaint, L. Cuzin, M. Surenaud, Y. Hénin, J. Lelièvre, B. Bonnet, G. Pialoux, I. Poizot-Martin, N. Ben Hamouda, A. Jackson, C. Flys, C. Guérin, J. Aboulker, J. Choppin, and O. Launay . Safety and Immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: Results of ANRS VAC18, a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial. AIDS Vaccine, Paris 2009, Oral abstract 04.01. 

C. Lacabaratz, A. Wiedemann, C. Durier, J. Lelièvre, M. Surenaud, G. Pialoux, D. Salmon-Céron, C. Desaint, O. Launay, J. Aboulker, J. Delfraissy and Y. Lévy . Analysis of cytokine expression of HIV-specific T cells in ANRS VAC18 trial of HIV-LIPO-5 vaccine,  AIDS Vaccine, Atlanta 2010, Poster 14.02. 

ANRS 12-26 – DYNABEADS

S. Diagbouga, C. Chazallon, M. Kazatchkine, P. Van De Perre, A. Inwoley, S. Mboup, M. Prince-David, A. Tenin, R. Soudré, J.P. Aboulker, L. Weiss. Successful implementation in West African laboratories of an alternative method to accurately enumerate at lower cost circulating CD4+ T lymphocytes in HIV-infected patients. XIVè International AIDS Conference, Barcelone, July 2002, abstract 10987. 

ANRS 12-10 VIETAR 

C. Nguyen Huu, N. Vo Thi Tuyet, M. Maynart, N.V Ngai, N.T.K.Cuc, P.V.Hung, C. Chazallon,   D.T.M.Ha, H.V.K.Binh, T.X.Lien, J.Y.Follezou. Difficulties in access to prevent opportunistic infections among HIV infected patients in Ho Chi Minh City. 2nd IAS Conference, Paris, 2003, Abstract 635. 

H.J. Fleury, Nguyen Thi Hoang Lan, Nguyen Huu Chi, Nguyen Van Ngai, Vo Tuyet Nhung, Truong Thi Xuan Lien, M. Maynart, C. Chazallon, J.P. Aboulker, and J.Y. Follezou. HIV drug resistance at baseline of the first HAART trial in Vietnam (ANRS 1210): Correlation with poor immunological and virological responses. XVII International HIV Drug Resistance Workshop, Sitgès, 2008, Abstract 131 (Paru également dans Antiviral Therapy 2008, 13 Suppl 3:A143.) 

ANRS 128 - PENTA 11-TICCH trial     

Riccardo Freguja; Hannah Poulson; Paola Del Bianco; Alexandra Compagnucci; Yacine Saidi; Carlo Giaquinto; Lynda Harper; Diana M. Gibb; Nigel J. Klein; Anita De Rossi. Long-Term Consequences of Planned Treatment Interruption in HIV-1–Infected Children. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle 2015. Poster 919

Ramos J, Melvin D, Medin G, Compagnucci A, Bleier J, Boscolo V, Barclay L, Ory S, Giaquinto C, Gibb D. on behalf of the PENTA Steering Committee. Neurocognitive and Quality of Life Outcomes in Children after Planned Treatment Interruptions: the randomized PENTA 11 trial. 19th Conference on Retroviruses and Opportunistic Infections, San Francisco, 5-8 March 2012, Poster

A. Compagnucci on behalf of the PENTA steering committed. Long term consequences of planned treatment interruptions in HIV infected children: results from the TICCH (Treatment Interruption in Children with Chronic HIV-infection) PENTA 11 trial. 3rd HIV Paediatric Workshop, Rome 15-16 July 2011.

Sefe D, Klein N, Mosconi I, Ricci E, Castro, H (nee Green), Jacobsen M, Bernardi S, Pillay D, Gibb DM, and De Rossi A, on behalf of the PENTA Steering Committee. Immunologic and viral dynamics among HIV-infected children after planned treatment interruption: a substudy of the Paediatric European Network for Treatment of AIDS (PENTA) 11 trial. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, 16-19 February 2010

Harrison L, Hamadache D, Bunupuradah T, Mazza A, Ramos Amador JT, Flynn J, Rampon O, Mellado Pena MJ, Floret D, Marczynska M, Puga A, Farrelly L, Riault Y, Lallemant M, Compagnucci A on behalf of the PENTA Trial Steering Committee. Adherence to ART and acceptability of planned treatment interruptions (PTI) in the PENTA 11 trial. 1st International Workshop on HIV Pediatrics, 17 – 18 July 2009, Cape Town, South Africa. (Poster P_90). 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town 19-22 July 2009

Lallemant M, Burger D, Lyall H, Buck L, Compagnucci A, Ramos Amador J.T, Mellado Pena M, Fregonese F, Campbell S, Rampon O, Castelli-Gattinara G, Cressey, Khoo S, Tréluyer J.-M, Green H, Saidi Y, Nadal D, Giaquinto C, Gibb D.M on behalf of the PENTA 11 study group. Pharmacokinetic and virological evaluations after stopping NNRTIs in children: a substudy of the PENTA 11 (TICCH) trial. XVI International AIDS Conference, Toronto, 13-18 August 2006. Poster MOPE0206 

ANRS 127 - 2IP

R. Landman, C. Chazallon, D. Descamps, C. Capitant, G. Peytavin, C. Katlama, G. Pialoux, M. Bentata, J.P. Aboulker and P. Yeni for the ANRS 127 study group. Efficacy and Safety of Dual PI Regimens for the Treatment of Antiretroviral-naïve HIV-1 Subjects: A Randomized Pilot Study (2IP ANRS 127). 15TH CONFERENCE on Retroviruses and Opportunistic Infections, Boston, 2008, abstract 779. 

R. Landman, C. Capitant, D. Descamps, C. Chazallon, G. Peytavin, C. Katlama, G. Pialoux, P. Perré, M. Bentata, P. Yeni, J.P. Aboulker, pour le groupe d’étude ANRS 127. Bithérapies d’inhibiteurs de la protéase (IP) pour le traitement initial de l’infection a vih-1: une étude pilote randomisée (2IP ANRS 127). 2ème  Forum de recherches fondamentales et cliniques sur le VIH, Paris, 14 et 15 avril 2008.  

G. Peytavin, C. Capitant, D. Descamps, C. Chazallon, C. Katlama, G. Pialoux, M. Bentata, J.P. Aboulker, P. Yeni and R. Landman for the ANRS 127 . Pharmacokinetic, Safety and Efficacy of two Dual PI Regimens FPV/r bid/ATV qd and SQV/ATV/r qd for the Treatment of Antiretroviral-naïve HIV-1 Subjects: A Randomized Pilot Study (ANRS 127). 9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, April 7-9 2008. 

L. Larrouy, C. Chazallon, R. Landman, C. Capitant, G. Peytavin, P.M. Girard, P. Yéni, J.P. Aboulker, F. Brun-Vézinet, D. Descamps, and ANRS 127 Study Group . Impact of Gag Genetic Determinants on Virological Response to Dual Boosted Protease Inhibitor combinations in Antiretroviral Naïve Patients. 16TH CONFERENCE on Retroviruses and Opportunistic Infections, Montreal, 2009, Abstract M-145. 

L. Larrouy, C. Chazallon, R. Landman, C. CapitantC, G. Collin, A. Storto, G. Peytavin, G. Pialoux, C. Katlama, P.M. Girard, P. Yeni, J.P. Aboulker, F. Brun-Vezinet, and D. Descamps . Impact of Gag genetic determinants and gag-pol frameshift stability on virological response to dual-boosted protease inhibitor combinations in antiretroviral-naive patients (ANRS 127 trial). 18th International HIV Drug Resistance Workshop, JUN 09-13, 2009 Ft Myers, Abstract: 57. 

ANRS 119 - INTERSTART 

Alain Venet, Marie-Lise Gougeon, Stéphanie Hamonic, Christine Lacabaratz, Daniel Sereni, Michèle Bentata, Isabelle Fournier, Jean-Pierre Aboulker, Yves Lévy and Jean-Michel Molina for the ANRS 119 Insterstart group. Intermittent IL-2 therapy induces the expansion of naïve and central memory CD4 T cells and has no impact on HIV-specific T cell responses in antiretroviral naïve HIV-infected patients.Immunological substudy of the ANRS 119 Interstart trial. Conference on Retroviruses and Opportunistic Infections 2007, Los Angeles [abstract 395]. 

JM Molina, Y Levy, I Fournier. Intermittent Interleukin-2 (IL-2) therapy to defer antiretroviral therapy in patients with HIV-infection (ANRS 119 - Interstart). ICAAC 2007, Chicago [oral communication]. 

J.M. Molina, Y. Levy, I. Fournier, T. Boulet, M. Bentata, G. Beck-Wirth, D. Sereni, F. Jeanblanc, F. Simon, J.P. Aboulker, and the ANRS 119-Interstart study team . Predictors of Slow Disease Progression in ART-naive HIV-1-infected Patients Treated with IL-2: 3 Year Extended Follow-up of the Interstart ANRS 119 Trial. 15th Conference on Retroviruses and Opportunistic Infections, Boston, 2008, Abstract 702. 

J.M. Molina, Y. Levy, I. Fournier, T. Boulet, M. Bentata, G. Beck-Wirth, D. Sereni, F. Jeanblanc, F. Simon, M.L. Gougeon, A. Venet and J.P. Aboulker for the ANRS 119 Study group . Interleukin-2 (IL-2) therapy to prevent CD4 T-cell loss and defer HAART in antiretroviral naive HIV-1 infected patients - Interstart ANRS 119 trial.17th International AIDS Conference, Mexico, 2008, abstract TUPDA105. 

F. Agbalika, I. Fournier, J. Brière, T. Boulet, S. Hamonic, M. Bentata, J.P. Aboulker, Y. Lévy, F.Simon and J.M. Molina for the ANRS 119 Study group . Impact of interleukin-2 (IL-2) therapy on Epstein Barr virus replication in naive HIV-infected patients : a sub-study of the Interstart ANRS 119 trial;17th International AIDS Conference, Mexico, 2008, abstract WEPE0124. 

M. Hanf, I. Charreau, F. Marcellin, I. Fournier, P. Tangre, Marchou B, Molina JM, Spire B, Aboulker JP. La qualité de vie des patients infectés par le VIH: comparaison des données obtenues dans 2 essais cliniques (Window ANRS 106 et Interstart ANRS 119) avec celles de l’enquête nationale représentative «VESPA» (ANRS EN12) et de la population générale française (INSEE 2003). 2ème Conférence francophone d'épidémiologie clinique ADELF-RFUEC, 23 mai 2008, Nancy, France.
 

ANRS 107 - PUZZLE 2 

A.M. Taburet, C. Piketty, L. Gérard, I. Vincent, C. Chazallon, F. Clavel, V. Calvez, J.P.  Aboulker, P.M Girard. Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovir in HIV infected patients with multiple treatment failures: a sub-study of Puzzle 2- ANRS 107 trial. 10th Conference on Retroviruses and Opportunistic Infections, Boston, 2003, abstract 537. 

C. Piketty, L. Gérard, C. Chazallon, V. Calvez, F. Clavel, A-M. Taburet, P.M. Girard JP. Aboulker and the Puzzle 2 study group. Virological and immunological impact of NNRTI withdrawal in HIV-infected patients with multiple treatment failures: a substudy of Puzzle 2 - ANRS 107 trial. 2nd IAS Conference, Paris, 2003, Abstract 544. 

C. Piketty, L. Gérard, C. Chazallon, V. Calvez, F. Clavel, A-M. Taburet, JP. Aboulker, P.M. Girard and the Puzzle 2 study group. Change In Genotypic Resistance Mutations After Introduction of Atazanavir (ATV) In HIV-Infected Patients With Multiple Treatment Failures : A Substudy of Puzzle2 - ANRS 107 Trial. ICAAC, Chicago, 2003, abstract 2069. 

I. Vincent, A. Barrail, C. Piketty, L. Gérard, C. Chazallon, JP. Aboulker, P.M. Girard, B. Kearney, A-M. Taburet and the Puzzle 2 study group. Pharmacokinetic parameters of Tenofovir when combined with Atazanavir/Ritonavir in HIV-infected patients with multiple treatment failures: a substudy of Puzzle 2-ANRS 107 trial. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec 2005.

C. Piketty, C. Chazallon, S. Lebel-Binay, A.G. Marcelin, V. Calvez, L. Gérard, J.P. Aboulker, F. Clavel . Evolution of protease genotypes and phenotypes in patients receiving atazanavir-based salvage therapy. XIV International HIV Drug Resistance Workshop, Quebec, 2005, poster 4.9. 

ANRS 106 - WINDOW 

Gallien S, Charreau I, Fonsart J, Mourah S, Kalidi I, Delobel P, Marchou B, Aboulker JP, Molina JM. Early changes in coagulation but not inflammatory biomarkers under intermittent ART: the randomized ANRS 106 WINDOW trial. HIV Drug Therapy, Glasgow, UK, 2-6 November 2014 (P019).

B. Marchou, J.M. Molina, P. Tangre, I. Charreau, M. Harel, J.M. Ragnaud, C. Katlama, T.  May, P.M. Girard, J.P. Aboulker and the ANRS 106 - WINDOW study group. A prospective, randomized, multicenter trial of intermittent therapy in HIV-infected patients with successful viral suppression under HAART. 2nd IAS Conference, Paris, 2003, abstract 613.

 J. Izopet, P. Tangre, B. Marchou, I. Charreau, K. Sandres-Sauné, V. Eliette, J.M. Ragnaud, C. Katlama, T. May, P.M. Girard, J.P. Aboulker, J.M. Molina and ANRS 106 study group. Patterns of HIV-1 resistance mutations after 8 weeks off therapy in patients enrolled in the randomized, open-label, ANRS 106-WINDOW trial. 2nd IAS Conference, Paris, 2003, (Oral communication).  

J. Izopet, P. Tangre, B. Marchou, I. Charreau, K. Sandres Sauné, J.M. Ragnaud, C. Katlama, T. May, P.M. Girard, J.M. Molina, J.P. Aboulker and ANRS 106 study group. ANRS 106– WINDOW: Predictive value of baseline PBMC HIV-1 DNA load for level of plasma HIV-1 RNA rebound 8 weeks after stopping antiretroviral therapy. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 2004, abstract H-581.

B. Marchou, J.M. Molina, P. Tangre, I. Charreau, S. Gueguen, J.M. Ragnaud, C. Katlama, T. May, P.M. Girard, P. Morlat, J.P. Aboulker, ANRS 106 study group . ANRS 106– Window: a prospective, randomized, multicenter trial of intermittent therapy in HIV-infected patients with successful viral suppression under HAART XV International AIDS Conference, Bangkok, 2004, AbstractWeOrB1285. 

B. Marchou, P. Tangre, I. Charreau, J. Izopet, P.M. Girard, T. May, J.M. Ragnaud, J.P. Aboulker, J.M. Molina, and ANRS 106 study group. Structured treatment interruptions in HIV-infected patients with high CD4 cell counts and virologic suppression: results of a prospective, randomized, open-label trial. 13th Conference on Retroviruses and Opportunistic Infections, Denver, 2006, Abstract 104.

P. Tangre, I. Charreau, M. Lafaurie, B. Marchou, C. Katlama, P. Morlat, A. Polaert, D. Vittecoq, J.P. Aboulker, J.M. Molina, and ANRS 106 study group. Predictive factors of thrombocytopenia in patients randomized to intermittent or continuous ART in the ANRS 106 Window trial. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, 2007, abstract 517.

I. Charreau,  G. Jeanblanc, P. Tangre, B. Marchou, J.P. Aboulker, J.M. Molina, I. Durand-Zaleski and the ANRS 106 Study Group.  Costs of intermittent versus continuous antiretroviral therapy in patients with controlled HIV infection. A substudy of the ANRS 106 Window trial. 11th European AIDS Conference, Madrid , 2007. Poster P19.5/04A

J. Izopet, B. Marchou, I. Charreau, K. Sauné, P. Tangre, J.M. Molina, J.P. Aboulker, the Window (ANRS 106) Study Team. HIV-1 Genotypic Resistance during Intermittent Antiretroviral Therapy and its Impact on CD4 Cell Counts and Antiviral Response. A Substudy of the ANRS 106 Window Trial. 11th European AIDS Conference, Madrid, 2007.

A. Samri, E. Nemes, I. Charreau, P. Tangre, B. Puissant, B. Marchou, J.P. Aboulker, J.M. Molina, B. Autran and G. Carcelain for the ANRS 106 Study team. HIV-Nef but bot HIV-Gag specific CD8 T cells increase breadth and magnitude during intermittent antiretroviral therapy compared to continuous treatment in patients with chronic HIV infection: the WINDOW-ANRS 106 trial. 15th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 2008, abstract  427.

M. Hanf, I. Charreau, F. Marcellin, I. Fournier, P. Tangre, B. Marchou, J.M. Molina, B. Spire, Aboulker JP. La qualité de vie des patients infectés par le VIH: comparaison des données obtenues dans 2 essais cliniques (Window ANRS 106 et Interstart ANRS 119) avec celles de l’enquête nationale représentative «VESPA» (ANRS EN12) et de la population générale française (INSEE 2003). 2ème Conférence francophone d'épidémiologie clinique ADELF-RFUEC, 23 mai 2008, Nancy, France. 

ANRS 103-PENTA 9-PENPACT 1 

Harrison L, Gibb DM, Fiscus S, Saïdi Y, Nastouli E, Harper L, Compagnucci A, Babiker A, Melvin A, Tudor-Williams G and the PENPACT 1 (PENTA 9/PACTG 390) Study Team. HIV-1 resistance after randomized virologic switch at 1,000 or 30,000 c/ml in children. CROI 2014, 3-6 March 2014, Boston. Poster 898.

PENTA and IMPAACT: A phase II/III randomised, open-label trial of combination antiretroviral regimens and treatment-switching strategies in HIV-1-infected antiretroviral naïve children. XVIII International AIDS Conference, 22nd July 2010, Vienna Austria. Presentation. 

Gibb DM, Compagnucci A, Green H, Lallemant M, Saidi Y, Ngo-Giang-Huong N, Taylor C, Mofenson L, Monpoux F, Tomé MIG, Marczyñska M, Nadal D, Wintergerst U, Kanjavanit S, Lyall H, Giaquinto C, Moye J. Treatment interruption in children with chronic HIV-infection: the results of the paediatric European network for treatment of AIDS (PENTA) 11 trial. Journal of the International AIDS Society 2008, 11(Suppl 1):O21 (10 November 2008). Poster

Gibb DM, Melvin A, Compagnucci A, McKinney R, Tudor-Williams G, Walker AS, Harper L, Hodge J, Powell C, Green H, Saidi Y, Ortiz AA, Toye M, Girard S, Mofenson L, Giaquinto C, Hughes M on behalf of the PENPACT 1 Trial. Choice of first-line ART regimen in PENPACT 1: a randomized trial of combination antiretroviral regimens and treatment switching strategies in antiretroviral naive children>30 days and <18 years of age. XV International AIDS Conference, 11-16 July 2004, Bangkok. Poster TuPeB4442. 

ANRS 101 – ESPRIT 

A. Labriola, E. Denning, N. Klimas, F. Gordin, on behalf of the US Department of Veterans Affairs National Trial Coordinating Center and the ESPRIT Study Group. Baseline characteristics associated with CD4+ response after three cycles of subcutaneous (SC) recombinant human interleukin-2 (IL2). 9th Conference on Retroviruses and Opportunistic Infections, Seattle, 2002, abstract 517M. 

  L. Weiss, J. Aboulhab, G.A. Babiker, J.D. Bebchuk, J. Darbyshire, D. Newburry, C. Capitant, J.P. Aboulker and the ESPRIT research group. Preliminary results of ESPRIT (Evaluation of Subcutaneous Proleukin® in a Randomised International Trial): Baseline predictors of CD4 T-cell response to Interleukin-2. 2nd IAS Conference, Paris, 2003, (Oral communication).  

ANRS 100 - PRIMSTOP 

Durier C, Goujard C, Roussillon C, Fournier I , Fagard C, Charreau I , Pialoux G, Hoen B , Rouzioux C , Aboulker JP, ANRS 100 PRIMSTOP & ANRS 112 INTERPRIM study groups. Viral Set Point after Cessation of Antiretroviral Therapy Initiated in Acute Primary HIV Infection. 21st Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, March 3-6, 2014. 

B. Hoen, M. Burgard, I. Fournier, C. Lacabaratz, F. Raffi, M. Lafaurie, J.M. Livrozet, C. Rouzioux, A. Venet, J.P. Aboulker, and the Primstop study team. Structured Treatment Interruptions (STI) in acute Seroconverters: Interim Results of the Multicenter Prospective PRIMSTOP Pilot Trial (ANRS 100). 9th Conference on Retroviruses and Opportunistic Infections, Seattle, 2002, abstract 530M. 

B. Hoen, C. Lacabaratz, I. Fournier, I. Charreau, M. Burgard, F. Raffi, P. Morlat, T. May, J.P. Aboulker, A. Venet, C. Rouzioux and the Primstop study group . Structured treatment interruptions (STI) in acute HIV seroconverters (AHS): preliminary results of the multicenter prospective PRIMSTOP pilot trial (ANRS 100). 10th Conference on Retroviruses and Opportunistic Infections, Boston, 2003, abstract 512. 

B. Hoen, I. Fournier, I. Charreau, C. Lacabaratz, M. Burgard, C. Arvieux, F. Pariente, J.P. Aboulker, A. Venet, C. Rouzioux, F. Raffi, and the Primstop study group . Structured Treatment Interruptions (STI) in primary HIV infection (PHI): Final Results of the Multicenter Prospective PRIMSTOP (ANRS 100) Pilot Trial. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2004, Abstract E-4. 

C. Delaugerre, M.L. Chaix, I. Charreau, G. Peytavin, M. Burgard, I. Fournier, J.P. Aboulker, B. Hoen, and C. Rouzioux. L90M Nelfinavir-Associated Resistance Mutation Emerged During Structured Treatment Interruption (STI) in Treated Acute HIV Infection (PRIMSTOP ANRS 100 Substudy). 45th ICAAC Meeting, New Orleans, 2005, Abstract 2811.    

ANRS 095 - PRIMOVAC 

C. Goujard, F. Marcellin, H. Chavez, V. Meiffrédy, C. Rouzioux, A. Venet, Y. Levy, Y. Taoufik, P. de Truchis, P. Morlat, R. Elhabib, V. Mazarin, J.F.  Delfraissy, J.P. Aboulker, and ANRS 095 Study Group. HIV immune and virological responses following the administration of IL-2 either alone or combined to ALVAC-HIV 1433 and HIV lipopeptides (LIPO-6T) in patients treated early with HAART during primary infection: the ANRS 095 randomized study. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2004, Abstract C-7. 

  D. Cooper, P. Yeni . Virological and immunological outcomes at 3 years following initiation of ART with regimens containing a NNRTI or PI or both: the INITIO trial. 12th Conference on Retroviruses and Opportunistic Infections, Boston, 2005, Abstract 165.

ANRS 093 - VACCIL 2 

Y. Levy, H. Gahery-Segard, C. Durier, A.-S. Lascaux, V. Meiffrédy, C. Goujard, J.-P. Cassuto, C. Rouzioux, R. Elhabib, J.-G. Guillet, J.-P. Aboulker, J.-F. Delfraissy, and the ANRS 093 study group. Immunological and Virological Efficacy of ALVAC-VIH 1433 and HIV Lipopeptides (Lipo-6T) Combined with SC IL-2 in Chronically HIV-infected Patients. Results of the ANRS 093 Randomized Study. 10th Conference on Retroviruses and Opportunistic Infections, Boston, 2003, Abstract 62. 

Y. Lévy, C. Durier, A.-S. Lascaux, V. Meiffrédy, C. Goujard, C. Rouzioux, R. Elhabib, J.-G. Guillet, J.-F. Delfraissy, J.-P. Aboulker and the ANRS 093 study group . Extended follow-up of theANRS 093 randomized study. Evaluation of ALVAC 1433 and the HIV lipopeptide (LIPO-6T) vaccines combined with IL-2 sc in chronically HIV-infected patients. 2nd IAS Conference, Paris, 2003, Late breaker (Oral communication) 

Y. Levy, H. Gahery-Segard, C. Durier, A.-S. Lascaux, V. Meiffrédy, C. Goujard, J.-P. Cassuto, C. Rouzioux, R. Elhabib, J.-G. Guillet, J.-P. Aboulker, J.-F. Delfraissy, ANRS 093 Study Group. Immunological and Virological Efficacy of ALVAC-HIV 1433 and HIV lipopeptides (Lipo-6T) Combined with SC IL-2 in Chronically HIV-infected Patients. Results of the ANRS 093 Randomized Study. AIDS Vaccine, New York, 2003, Abstract G2-5. 

C. Rouzioux, C. Durier, M. Burgard, A.-S. Lascaux, V. Meiffrédy, C. Goujard, R. ElHabib, J.-P. Aboulker, J.-F. Delfraissy, Y. Levy, ANRS093 Study group. Evaluation of HIV DNA Levels in the ANRS 093 Randomized Study of ALVAC-HIV 1433 and HIV Lipopeptides (Lipo-6T) Vaccination Combined with SC IL-2 in Chronically HIV-infected Patients. AIDS Vaccine, New York, 2003; Abstract G2-6. 

  Y. Levy, H. Gahery-Segard, C. Durier, A.-S. Lascaux, V. Meiffredy, A. Cassuto, C. Goujard, C. Rouzioux, R. El Habib, M. Beumont, J.-G. Guillet, J.-F. Delfraissy, J.-P. Aboulker, and ANRS 093 Study Group. Evaluation of T-cell Immunogenicity of a Vaccination Strategy Combining ALVAC-HIV (vCP 1433) and HIV Lipopeptides (Lipo-6T) Followed by SC IL-2 in Chronically HIV-infected Patients. Results of the ANRS093 Randomized Study. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2004, Abstract C-8. 

Y. Levy, C. Durier, V. Meiffrédy, H. Gahery-Segard, A.-S. Lascaux, C. Goujard, J.P. Cassuto, C. Rouzioux, R. Elhabib, M. Beumont-Mauviel, J.G. Guillet, M. Kazatchkine, J.F. Delfraissy, J.P. Aboulker, and the ANRS 093 study group. ANRS, Chiron France and Aventis Pasteur France. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals: long-term follow-up of the ANRS 093 trial. 12th Conference on Retroviruses and Opportunistic Infections, Boston, 2005, Abstract 133. 

C. Durier, H. Gahery-Segard, M.Surenaud, J.-P.  Aboulker, J.-G. Guillet, Y. Levy and the ANRS 093 study group. The magnitude of HIV-specific CD8 T cell responses is associated with a sustained control of viremia following therapeutic immunization in chronically HIV-1 infected individuals. AIDS Vaccine, Montreal, 2005, Abstract 123. 

Y. Levy, C. Durier,  V. Meiffredy, H. Gahery-Segard, A.-S.  Lascaux, C. Goujard,  J.-P. Cassuto, C. Rouzioux, M. Resch, R. El Habib,  M. Beumont-Mauviel, J.-G. Guillet, M. Kazatchkine, J.-F.  Delfraissy, J.-P.  Aboulker and the ANRS 093 study group. Predictive factors associated with a sustained control of viremia following therapeutic immunization in chronically HIV-1 infected individuals. AIDS Vaccine, Montreal, 2005, Abstract 124.   

ANRS 089 - INITIO 

D. Cooper and P. Yeni. Virological and Immunological Outcomes at 3 Years following Initiation of ART with Regimens Containing a NNRTI or PI or both: The INITIO Trial. 12th CROI, Boston, 2005, LB 165. 

B.R. Feeney, C. Chazallon, N. O’Brien, V. Meiffrédy, R.L. Goodall, D.A. Cooper, J.P. Aboulker, P. Yeni, P.W.G. Mallon on behalf of the INITIO Trial International Co-ordinating Committee. Peripheral blood mononuclear cell mitochondrial DNA (mtDNA) and mitochondrial RNA (mtRNA) does not predict lactic acidosis or symptomatic hyperlactatemia for HIV-infected patients on antiretroviral therapy : a sub-study of the INITIO Trial. 17th CROI, San Francisco, 2010, O-202. 

PENTA 8-PERA 

Giaquinto C, Green H, De Rossi A, Saïdi Y, Compagnucci A, Girard S, Castelli-Gattinara G, della Negra M, Pinto J, De Souza Marques HH, Lyall EGH and Gibb DM on behalf of the PENTA 8 study group. A randomised trial of resistance testing versus no resistance testing in children with virological failure: the PERA (PENTA 8) trial. 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janerio. Oral and poster presentation WeOa0106.

ANRS 087 – PENTA 7 

C. Litalien, C. Giaquinto, A. Faye, F. Mechinaud, I. Grosch, A. Compagnucci, E. Jacqz-Aigrain. Nelfinavir doses should be increased in infants less than 3 months. XIII International AIDS Conference, Durban, 2000, abstract Mo PEB 2213. 

A. Faye, A. Compagnucci, Y. Saïdi, for the PENTA 7 executive committee. Evaluation of toxicity, tolerability and antiviral activity of early d4T+ddl+Nelfinavir (NFV) therapy in HIV-1 vertically infected infants: 24 week preliminary results from the PENTA 7 study. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, 2001, poster 678.

A. Compagnucci, Y. Saïdi, ML. Chaix, C. Rouzioux, D. Gibb, C. Giaquinto, A. Faye, for the PENTA 7 committees. Difficulties to achieve suppression of viral replication in vertically HIV-1 infected infants early treated with d4T+ddI+NFV. ). 9th Conference on Retroviruses and Opportunistic Infections, Seattle, 2002, abstract 809W. 

 A. Compagnucci, Y. Saïdi, A. Faye, L. Ciria Calavia, D.M. Gibb, S. Girard, M.H. Quernin, L. Harper, C. Giaquinto and E. Jacqz-Aigrain, on behalf of the Paediatric European Network for Treatment of AIDS (PENTA) Committees. Impact of nelfinavir (NFV) and its active metabolite M8 through levels (TL) on virologic response from primary HIV-1 vertically infected children treated with stavudine (D4T), didanosine (DDI) and NFV in the Penta 7 study. 2nd IAS Conference, Paris, 2003, abstract 1095. 

A. Compagnucci, Y. Saïdi, L. Harper, M.L. Navarro, S. Girard, S. Walker, M. Debré, D.M. Gibb, O. Rampon, E. Lachassine, T. Schmitz, G. Giaquinto, J.P. Aboulker, and A. Faye, on behalf of the PENTA steering committee. Three year outcomes in children treated with HAART before 3 months of age in the PENTA 7 trial. XV International AIDS Conference, Bangkok, 2004, Abstract B11956. 

A. Compagnucci, Y. Saïdi, L.M. Harper, S. Blanche, C. Gabiano, I. de José Gomez, G. Notheis, D.M. Gibb, C. Giaquinto and A. Faye for the PENTA 7 committees. Does early treatment provide long term benefit in HIV-1 infected infants ? Five year outcomes in children treated before 3 months of age in the PENTA 7 Trial. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, 2007, abstract R-151.

ANRS 084 - PENTA 5 

Gibb. D. M. for the PENTA 5 Executive and the PENTA Steering Committee. A randomised trial evaluating three NRTI regimens with and without Nelfinavir in HIV-infected children: 48 week follow-up from the PENTA 5 trial. Oral presentation at 5th International Congress on Drug Therapy in HIV Infection, Glasgow 22-26 October 2000 also published in AIDS 2000, Vol 14, supp4 p.58 (abstractPL6.8) 

Gibb DM, Walker AS, Giaquinto C, Harper L, Compagnucci A, Saidi Y, Aboulker JP, Babiker A, Debré M, Darbyshire JH on behalf of the PENTA 5 Steering Committee. 96 week follow-up of the PENTA 5 trial; comparing ZDV+3TC, ZDV+ABC and 3TC+ABC with or without NFV in ART naive children XIV World AIDS Conference, Barcelona, Spain, 7-12 July 2002. Poster TuPpB2051) 

D. Gibb, C. Giaquinto, S. Walker, L. Harper, A. Compagnucci, Y. Saïdi, C. Moulinier, J.-P. Aboulker, A. Babiker, M. Debré, J. Darbyshire, the PENTA 5 Steering Committee . Three-year follow-up of the PENTA 5 trial. 10th Conference on Retroviruses and Opportunistic Infections, Boston, 2003, abstract 874.  

ANRS 081 – TRIANON 

O. Launay, G. Peytavin, P. Flandre, L. Gérard, V. Joly, J.P. Aboulker, P. Yeni pour l’essai ANRS-081. Interaction pharmacocinétique entre la nevirapine et l’indinavir au cours de l’essai ANRS 081. 3e Séminaire Annuel de Recherche Clinique sur l’Infection par le VIH, ANRS Paris, 1999, A37.

O. Launay, G. Peytavin, P. Flandre, L. Gérard, C. Levy, V. Joly, J.P. Aboulker, P. Yeni. Pharmacokinetic (PK) Interaction between Nevirapine (NVP) and Indinavir (IDV) in ANRS 081 Trial. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000, Toronto, abstract 1632. 

O. Launay, L. Gérard, L. Morand-Joubert, P. Flandre, S. Guiramand, V. Joly, G. Paytavin, A. Certain, C. Jacomet, S. Rivet, J.P. Aboulker, P. Yeni for the ANRS 081 Study Group. Comparative antiviral activity and toxicity of nevirapine (NVP) versus lamivudine (3TC), in combination with stavudine (d4T) and indinavir (IDV), for the treatment of HIV-1 infected patients. 8th Conference on Retroviruses, Chicago, February 2001, abstract 326.
 

G. Peytavin, P. Flandre, O. Launay, L. Gérard, L. Morand-Joubert, C. Levy, S. Izard, V. Joly, J.P. Aboulker and P. Yeni for the ANRS 081 Study Group. Relationship between indinavir (IDV) and nevirapine (NVP) plasma concentrations and virologic response in HIV-1 infected patients in Trianon – ANRS 081 trial. 8th Eurpean Conference on Clinical Aspects and Treatment of HIV-infection, Athens, October 2001, abstract P163. 

L. Morand-Joubert, F. Marcellin, O. Launay, S. Guiramand-Hugon, L. Gérard, P. Yéni, J.P. Aboulker et le groupe d'étude Trianon . Analyse de l'ADN proviral et des facteurs associés à sa variation, dans l'essai Trianon (ANRS 081). 5è Séminaire annuel de Recherche Clinique sur l'Infection par le VIH, ANRS 2002, Paris, p. 81-82. 

C. Verstuyft, F. Marcellin, L. Morand-Joubert, O. Launay, G. Peytavin, L. Gerard, L. Becquemont, J. P. Aboulker. Impact of MDR1 (C3435T) genetic polymorphism in patients naïve treated with HAART including indinavir. 10th Conference on Retroviruses and Opportunistic Infections, Boston, 2003, abstract 522.  

ANRS 079 - IL2-SC 

Y. Levy, C. Durier, A.S. Lascaux, C. Capitant, C. Michon, L. Weiss, E. Oksenhendler, J.A. Gastaut, C. Goujard, C. Rouzioux, J.P. Aboulker, J.F. Delfraissy, and the ANRS 079 Study Group. Long term efficacy of subcutaneous IL-2 therapy in HIV-infection final analysis of the ANRS 079 randomized trial and long term follow-up. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, 2002, abstract 514-M. 

M. Burgard, C. Durier, C. Capitant, A.S. Lascaux, C. Michon, E. Netzer, C. Goujard, V. Foubert, J.P. Aboulker, J.F. Delfraissy, Y. Levy, C. Rouzioux, and the ANRS 079 Study Group. Long term efficacy of subcutaneous IL-2 therapy in HIV-infection proviral DNA in patients of the ANRS 079 trial. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, 2002, abstract 515-M. 

 ANRS 073 - NOVAVIR 

V. Joly, P. Flandre, V. Meiffrédy, F. Brun-Vezinet, I. Carrière, J-A. Gastaut, R. Fior, G. Remy, B. Bazin, A. Certain, J.P. Aboulker, P. Yeni and the NOVAVIR Study Group, ANRS, Paris, France. Tolerance and Antiviral Efficacy of Triple Drug Combination Including Indinavir in Nucleoside Pretreated HIV-Infected Patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, abstract 1986.

V. Joly, P. Flandre, V. Meiffrédy, J. Izopet, F. Brun-Vézinet, C. Tamalet, I. Carrière, J.A. Gastaut, R. Fior, G. Remy, B. Bazin, A. Certain, J-P. Aboulker, P. Yeni and the NOVAVIR Study Group, ANRS, Paris, France. Similar Efficacy of AZT and d4T in Combination with 3TC and Indinavir in the Treatment of HIV-Infected Patients Previously Exposed to Nucleosides but Naive for 3TC, d4T and Protease Inhibitors (NOVAVIR Trial) 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 2000, abstract 696.

V. Joly, P. Flandre, V. Meiffrédy, S. Hazebrouck, M. Harel, J-P. Aboulker, and P. Yeni. ANRS, Paris, France. Assessment of Lipodystrophy in Patients Previously exposed to AZT, ddI or ddC but naive for d4T and Protease Inhibitors (PI), and Randomized Between d4T/3TC/Indinavir, and AZT/3TC/Indinavir (NOVAVIR Trial). 8th Conference on Retroviruses and Opportunistic Infections, Chicago, 2001, abstract 539.   

D. Descamps, P. Flandre, J. Izopet, C. Tamalet, A. Ruffault, F. Zeng, V. Meiffrédy, G. Peytavin, J-P. Aboulker, V. Joly, P. Yeni and F. Brun-Vezinet, ANRS, Paris, France. Genotypic Resistance to Zidovudine (ZDV) and Relationship to Subsequent Response in NOVAVIR ANRS 073 Trial. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, 2001, abstract 438.

D. Descamps, P. Flandre, V. Joly, J. Izopet, G. Peytavin, C. Tamalet, A. Ruffault, F. Zeng,
V. Meiffrédy, J-P. Aboulker, P. Yeni and F. Brun-Vezinet, ANRS, Paris, France.
Genotypic Resistance Analyses at Time to Failure in NOVAVIR ANRS 073 Trial. Antiviral Therapy 2001; 6 (supplement 1) : 75. 5th International Workshop on HIV Drug Resistance & Treatment Strategies, Scottsdale, 2001, abstract 98.
  

ANRS-072 - TRILEGE 

G. Pialoux, F. Raffi, F. Brun-Vezinet, V. Meiffrédy, J-P. Aboulker and ANRS 072 Study Group. ”Prospective Randomized Evaluation of Three Maintenance Regimens for HIV Infected Adults Receiving Induction Therapy with Zidovudine (ZDV), Lamivudine (3TC), and Indinavir (IDV). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997, abstract 188.

F. Raffi, G. Pialoux, F. Brun-Vezinet, J-A. Gastaut, P. Dellamonica, J-F. Delfraissy, V. Meiffrédy, P. Flandre, J-P. Aboulker, for the ANRS 072 Study Group. Univ Hosp. Nantes; Paris ; Marseille ; Nice ; and INSERM SC10, Villejuif, France. Results of TRILEGE trial : a Comparison of Three Maintenance Regimens for HIV Infected Adults Receiving Induction Therapy with Zidovudine (ZDV), Lamivudine (3TC) and Indinavir (IDV). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1998, abstract LB15.

D. Descamps, V. Calvez, P. Flandre, G. Pialoux, F. Raffi, C. Delaugerre, G. Collin, V. Meiffrédy, G. Peytavin, J-P. Aboulker, F. Brun-Vezinet and the ANRS 072 Trilège group. Genotypic Resistance Analyses of Plasma HIV- RNA in Patients Failing to the Maintenance Therapy in Trilège trial. 4th International Congress on Drug Therapy in HIV Infection, Glasgow, 1998, OP3.3 ; 2nd Séminaire de Recherche Clinique sur l’Infection par le VIH ; ANRS, Paris, 1998, abstract 012.

D. Descamps, G. Peytavin, V. Calvez, P. Flandre, V. Meiffrédy, F. Raffi, G. Pialoux, J.P. Aboulker, F. Brun-Vezinet and the Trilège study group, France. Virologic Failure, Resistance and Plasma Drug Measurements in Induction Maintenance Therapy Trial (ANRS 072, Trilège). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 493.

  J-P. Aboulker, D. Scott, M. Prud’homme, V. Meiffrédy, G. Pialoux, F. Brun-Vezinet and F. Raffi for the ANRS 072 Trial, France. CD4 T-Cell Recovery is Slower in Patients Experiencing Viral Load Rebounds during HAART. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000, abstract 343.

 ANRS-064 – VIDREA 

F. Lucht, I. Charreau, F. Biron, A. Fresard, S. Hazebrouck, Y. Saidi, A. Boibieux, J. Puel, J.M. Seigneurin, J.P. Aboulker, D. Peyramond, and the ANRS 064 trial group . A randomised phase II trial comparing two different doses of hydroxyurea (HU) plus didanosine (ddI), ddI alone or ddI plus zidovudine (ZDV), in HIV-1 infected naïve patients with CD4 lymphocytes between 250 and 500/mm3. 38è Conférence Internationale de Chimiothérapie Anti-infectieuse, San Diego, CA, 1998. 

  Posters : 3rd Conference on Retroviruses and Opportunistic Conference, Washington, DC, 1996. 

F. Biron, F. Lucht, D. Peyramond, A. Fresard, B. Contamin, T. Vallet, F. Nugier, J. Grange, S. Malle, F. Hamedi-Sangsari, B. Verrier, J. Vila . Follow up of HIV1 infected patients treated with didanosine and hydroxyurea combination. 3rd Conference on Retroviruses and Opportunistic Conference, Washington, DC, 1996. 

B. Conway, J. Raboud, J.S.G Montaner, M.V. O'Shaughnessy, C. Zala. Evaluation of viral dynamics in patients on antiretroviral therapy. 3rd Conference on Retroviruses and Opportunistic Conference, Washington, DC, 1996. 

J.S.G. Montaner, C. Zala, J.M. Raboud, B. Conway, P. Patenaude, S. Rae, M.T. Schechter, M.V. O'Shaughnessy. A pilot study of hydroxyurea (Ho-urea) as adjuvant therapy among patients with advanced HIV disease receiving didanosine (ddI) therapy. 3rd Conference on Retroviruses and Opportunistic Conference, Washington, DC, 1996. 

  W.Y. Gao, B.S. Zhou, D.G. Johns, H. Mitsuya, Y. Yen. 3rd Conference on Retroviruses and Opportunistic Conference, Washington, DC, 1996. 

  ANRS-048 – IL-2 

Y. Levy, C. Capitant, S. Houhou, I. Carrière, J.A. Gastaut, J.P. Viard, J.P. Aboulker. IL2 in HIV patients: a randomized trial comparing SC, PEG, CIV IL2 with AZT+ddI. 12th World AIDS Conference, Geneva, July 1998, abstract 41229. 

Y. Levy, C. Capitant, S. Houhou, I. Carrière, J.A. Gastaut, J.P. Viard, L. Boumsell, E. Gomard, C. Rabian, L. Weiss, and the ANRS 048 Study Group. Immunological efficacy of IL-2 therapy in HIV patients. Results of a randomised trial comparing SC, PEG, CIV IL-2 with antiretroviral therapy. The American Society of Hematology, Miami, December 1998, abstract 681; 

Y. Levy, C. Capitant, K. Bouchenafa, C. Durier, J.P. Viard, C. Goujard, J.F. Delfraissy, J.P. Aboulker, and the ANRS 048 Study Group. Long term (3 years) efficacy of IL-2 therapy in HIV-infected patients. Results of the follow-up of the randomized ANRS 048 trial. XIII International AIDS Conference, Durban, July 2000, abstract 2461. 

  ANRS-017 - DELTA 

I. Charreau, K. Chemlal, P. Yeni, J. Dormont, M. Seligmann, J.P. Aboulber on behalf of the Delta Coordinating Committee. Reduced risk of progression to HIV encephalopathy with ddI or ddC in combination to AZT compared to AZT Alone. Vth Conference on Retroviruses and Opportunistic Infections, Chicago, 1998, abstract 458.

S. Abgrall, I. Charreau, J. Bloch, V. Joly, J. Reynes, P. Yeni, J.P. Aboulber on behalf of the Delta Coordinating Committee. Risk factors for esophageal candidiasis in HIV infection. Vth Conference on Retroviruses and Opportunistic Infections, Chicago, 1998, abstract 492.

J. P. Aboulker, V. Chams-Harvey, P. Flandre, S. Delarue, S. Leonardo, P. Yeni, D. Descamps, F. Brun-Vézinet. Slower disease progression and greater CD4 response to antiretroviral treatment in HIV patients co-infected with GBV-C. 10th Conference on Retroviruses and Opportunistic Infections, Boston, 2003, abstract 849.  

  ANRS-006 - ALPHA 

C. Tournerie, I. Charreau on behalf of the MRC/ANRS International Coordinating Committee for the European/Australian Alpha trial. Cotrimoxazole (TMP-SMX) for primary prophylaxis of Toxoplasma encephalitis in advanced HIV patients. IXth International AIDS Conference, Berlin, 1993, abstract WS-B13-2.